Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

Ghassan K. Abou-Alfa, MD
Published: Tuesday, Jul 26, 2016


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
 

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x